Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Amgen Inc. is a global biotechnology company focused on the discovery, development, manufacturing, and commercialization of human therapeutics. The company operates primarily within the biopharmaceutical industry, targeting serious illnesses with high unmet medical need. Amgen’s products are largely biologics, including recombinant proteins, monoclonal antibodies, and other advanced therapies, with core therapeutic areas spanning oncology, cardiovascular disease, inflammation, bone health, nephrology, and rare diseases.
Amgen generates revenue through the sale of branded medicines to healthcare providers, hospitals, and wholesalers, primarily in developed markets. Key products include therapies for cancer, autoimmune disorders, osteoporosis, and cardiovascular conditions, as well as biosimilars that compete with established biologic drugs. Founded in 1980, Amgen was among the earliest biotechnology companies to successfully commercialize recombinant DNA-based medicines, evolving from a research-driven startup into one of the world’s largest independent biotechnology firms.
Business Operations
Amgen’s operations are organized around the research, development, manufacturing, and commercialization of biologic medicines and biosimilars. Revenue is primarily driven by sales from its Oncology, Inflammation, Cardiovascular, Bone Health, and Rare Disease therapeutic portfolios. The company maintains integrated capabilities, controlling significant in-house biologics manufacturing facilities, advanced drug development platforms, and a global commercial organization.
The company operates both domestically and internationally, with manufacturing and research sites across North America, Europe, and Asia. Amgen also maintains a growing biosimilars business through its Biosimilars segment, leveraging biologics manufacturing expertise to produce lower-cost alternatives to branded biologic therapies. Strategic collaborations with research institutions and pharmaceutical partners support pipeline development, while subsidiaries manage regional commercialization and manufacturing activities.
Strategic Position & Investments
Amgen’s strategic direction emphasizes innovation in biologics, expansion of its biosimilars portfolio, and disciplined capital allocation through targeted acquisitions and internal research investment. Growth initiatives include advancing late-stage clinical programs, lifecycle management of existing products, and applying human genetics and data-driven approaches to drug discovery. The company invests heavily in research and development to sustain a robust clinical pipeline.
Notable strategic investments include the acquisition of Horizon Therapeutics, which expanded Amgen’s presence in rare and autoimmune diseases, and earlier acquisitions such as ChemoCentryx, strengthening its inflammation and nephrology portfolio. Amgen is also investing in emerging modalities, including next-generation biologics and digital-enabled drug development technologies, while maintaining a conservative balance sheet and returning capital to shareholders through dividends and share repurchases.
Geographic Footprint
Amgen is headquartered in North America, with its corporate headquarters located in Thousand Oaks, California. The company has a substantial presence across North America, Europe, and the Asia-Pacific region, with operations spanning research, manufacturing, and commercial activities. The United States remains its largest single market by revenue.
Internationally, Amgen operates subsidiaries and affiliates across Europe, Japan, China, Latin America, and other key global markets. The company’s geographic diversification supports both revenue growth and risk mitigation, while international manufacturing and distribution networks enable global supply of complex biologic medicines.
Leadership & Governance
Amgen is led by an experienced executive team with deep expertise in biotechnology, pharmaceuticals, and global operations. The company emphasizes long-term value creation through scientific excellence, operational discipline, and patient-focused innovation, guided by a governance framework aligned with shareholder interests and regulatory compliance.
Key members of Amgen’s leadership include:
- Robert A. Bradway – Chairman and Chief Executive Officer
- Peter H. Griffith – Executive Vice President and Chief Financial Officer
- David M. Reese – Executive Vice President, Research and Development
- Murkali Krishnan – Senior Vice President, Global Analytics and Data Sciences
- Michael V. Nicholson – Executive Vice President and Chief Human Resources Officer
The leadership team’s strategic vision centers on sustaining innovation leadership in biotechnology while maintaining financial strength and global operational excellence.